Novacyt S.A. Director/PDMR Shareholding (1942F)
November 13 2020 - 1:00AM
UK Regulatory
TIDMNCYT
RNS Number : 1942F
Novacyt S.A.
13 November 2020
Novacyt S.A.
("Novacyt" or the "Company")
Director/PDMR Shareholding
Paris, France and Camberley, UK - 13 November 2020 - Novacyt
(EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in
clinical diagnostics, announces that it has been notified that, on
12 November 2020, Jean-Pierre Crinelli, a Non-Executive Director of
the Company, purchased 1,541 ordinary shares of EUR1/15 each in the
Company at a price of EUR9.70 per share.
Following the purchase, Mr Crinelli is interested in 30,773
ordinary shares representing 0.04% of the issued share capital.
This amount includes 8,000 ordinary shares purchased by Mr Crinelli
at a price of EUR1.274 per share on 20 March 2020 which
inadvertently was not disclosed by Mr Crinelli at the time.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name
Jean-Pierre Crinelli - Non-Executive
Director
-------------------------------- ---------------------------------------
2. Reason for the Notification
-------------------------------------------------------------------------
a) Position/status See 1(a) - classified as
a PDMR of the Company
-------------------------------- ---------------------------------------
b) Initial notification/ Amendment Initial Notification
-------------------------------- ---------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name Novacyt S.A.
-------------------------------- ---------------------------------------
b) LEI 213800BWAC2BF295EG28
-------------------------------- ---------------------------------------
4. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------------
a) Description of the Financial ordinary shares of EUR1/15
instrument, type of instrument each
-------------------------------- ---------------------------------------
Identification code FR0010397232
-------------------------------- ---------------------------------------
b) Nature of the transaction Acquisition of Ordinary Shares
-------------------------------- ---------------------------------------
c) Price(s) and volume(s) Price Volume
EUR9.70 1,541
-------
-------------------------------- ---------------------------------------
d) Aggregated information:
-- Aggregated volume N/A Single transaction as
-- Price above Price Volume
EUR9,70 1,541
-------
-------------------------------- ---------------------------------------
e) Date of the transaction
12 November 2020
-------------------------------- ---------------------------------------
f) Place of the transaction Paris Euronext Growth
-------------------------------- ---------------------------------------
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name
Jean-Pierre Crinelli - Non-Executive
Director
-------------------------------- ---------------------------------------
2. Reason for the Notification
-------------------------------------------------------------------------
a) Position/status See 1(a) - classified as
a PDMR of the Company
-------------------------------- ---------------------------------------
b) Initial notification/ Amendment Initial Notification
-------------------------------- ---------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name Novacyt S.A.
-------------------------------- ---------------------------------------
b) LEI 213800BWAC2BF295EG28
-------------------------------- ---------------------------------------
4. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------------
a) Description of the Financial ordinary shares of EUR1/15
instrument, type of instrument each
-------------------------------- ---------------------------------------
Identification code FR0010397232
-------------------------------- ---------------------------------------
b) Nature of the transaction Acquisition of Ordinary Shares
-------------------------------- ---------------------------------------
c) Price(s) and volume(s) Price Volume
EUR1.274 8,000
-------
-------------------------------- ---------------------------------------
d) Aggregated information:
-- Aggregated volume N/A Single transaction as
-- Price above Price Volume
EUR1.274 8,000
-------
-------------------------------- ---------------------------------------
e) Date of the transaction
20 March 2020
-------------------------------- ---------------------------------------
f) Place of the transaction Paris Euronext Growth
-------------------------------- ---------------------------------------
Contacts
Novacyt SA
Graham Mullis, Chief Executive Officer
Anthony Dyer, Chief Financial Officer
+44 (0)1276 600081
SP Angel Corporate Finance LLP (Nominated Adviser and
Broker)
Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
+44 (0)20 3470 0470
Numis Securities Limited (Joint Broker)
Freddie Barnfield / James Black
+44 (0)20 7260 1000
FTI Consulting (International)
Victoria Foster Mitchell / Mary Whittow
+44 (0)20 3727 1000
victoria.fostermitchell@fticonsulting.com /
mary.whittow@fticonsulting.com
FTI Consulting (France)
Arnaud de Cheffontaines
+33 (0)147 03 69 48
arnaud.decheffontaines@fticonsulting.com
About Novacyt Group
The Novacyt Group is an international diagnostics business
generating an increasing portfolio of in vitro and molecular
diagnostic tests. Its core strengths lie in diagnostics product
development, commercialisation, contract design and manufacturing.
The Company's lead business units comprise of Primerdesign and
Lab21 Products, supplying an extensive range of high-quality assays
and reagents worldwide. The Group directly serves microbiology,
haematology and serology markets as do its global partners, which
include major corporates.
For more information please refer to the website: www.novacyt.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHGPGBAGUPUGMP
(END) Dow Jones Newswires
November 13, 2020 02:00 ET (07:00 GMT)
Novacyt (LSE:NCYT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novacyt (LSE:NCYT)
Historical Stock Chart
From Apr 2023 to Apr 2024
